Morgan Stanley Downgrades Esperion Therapeutics (ESPR) to Underweight
Tweet Send to a Friend
Morgan Stanley analyst Jeffrey Hung downgraded Esperion Therapeutics (NASDAQ: ESPR) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
